MUMBAI, India & WARREN, N.J., USA – February 27, 2026
Cipla Limited announced the U.S. launch of Liraglutide Injection 18 mg/3 mL (6 mg/mL) prefilled pens, the generic equivalent of Saxenda®, strengthening its North American portfolio in the rapidly expanding GLP-1 weight management therapy segment. The launch follows Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (USFDA) granted to its partner, Orbicular Pharmaceuticals, enabling immediate commercialization across the United States.
Strengthening Cipla’s U.S. Peptide Portfolio
The newly launched generic liraglutide injection is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in eligible adult and pediatric populations. Delivered via a single-patient-use multidose prefilled injector pen, liraglutide is a synthetic analog of the human glucagon-like peptide-1 (GLP-1) hormone, designed to regulate blood glucose levels and promote weight loss by enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite.
Cipla will lead marketing and distribution efforts in the U.S., leveraging its established commercial infrastructure and deep channel relationships to ensure reliable availability. Company leadership highlighted the launch as a key milestone in its differentiated peptide portfolio, reinforcing its strategy to expand access to complex generics in regulated markets. The addition positions Cipla among a limited group of manufacturers offering generic versions of both Victoza® and Saxenda® in the U.S. market.
Expanding Access in the High-Growth GLP-1 Market
Advertisement
GLP-1 receptor agonists represent one of the fastest-growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, robust clinical outcomes, and increasing physician adoption. According to IQVIA MAT December 2025 data referenced in the release, the total addressable U.S. market opportunity for GLP-1 therapies in weight management was approximately USD 127 million.
Liraglutide was first approved for medical use in the European Union in 2009 and in the United States in 2010, later receiving U.S. FDA approval for chronic weight management in adults in 2014, followed by pediatric indications.The availability of a generic version is expected to support broader affordability and patient access in a category that has experienced significant demand growth.
Regulatory Milestone and Commercial Execution
Orbicular Pharmaceuticals, the ANDA holder for generic liraglutide injection, secured regulatory approval from the USFDA, enabling Cipla’s immediate market entry. The collaboration underscores the importance of strategic partnerships in advancing complex injectable generics, particularly peptide-based drug-device combination products.
Cipla operates 46 manufacturing sites globally and supplies more than 1,500 products across 80+ markets.The company continues to focus on complex generics and differentiated formulations as part of its long-term growth strategy in North America and other regulated markets.
The launch of generic liraglutide strengthens Cipla’s presence in metabolic and obesity care while reinforcing its broader commitment to expanding access to high-quality, affordable medicines at scale. As obesity remains a major global health challenge, increased availability of cost-effective GLP-1 therapies may play a critical role in improving long-term patient outcomes.
Source: Cipla press release
